APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitor Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitor Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitor Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitor Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitor Drug include UCB, Shanghai Pharmaceuticals Holding Co., Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Amgen Inc., AbbVie Inc. and PROBIOMED, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tumor Necrosis Factor Inhibitor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Inhibitor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Inhibitor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Inhibitor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Inhibitor Drug Segment by Company

UCB

Shanghai Pharmaceuticals Holding Co., Ltd.

Johnson & Johnson

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

Amgen Inc.

AbbVie Inc.

PROBIOMED

LEO Pharma

EPIRUS Biopharmaceuticals

CASI Pharmaceuticals

Tumor Necrosis Factor Inhibitor Drug Segment by Type

Humira

Enbrel

Biosimilars

Cimzia

Simponi

Remicade

Tumor Necrosis Factor Inhibitor Drug Segment by Application

Juvenile Idiopathic Arthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Crohn’s Disease

Others

Tumor Necrosis Factor Inhibitor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tumor Necrosis Factor Inhibitor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tumor Necrosis Factor Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tumor Necrosis Factor Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Inhibitor Drug Industry Trends Table 2. Tumor Necrosis Factor Inhibitor Drug Industry Drivers Table 3. Tumor Necrosis Factor Inhibitor Drug Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Inhibitor Drug Industry Restraints Table 5. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Inhibitor Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Manufacturers Table 9. Global Tumor Necrosis Factor Inhibitor Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Tumor Necrosis Factor Inhibitor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tumor Necrosis Factor Inhibitor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tumor Necrosis Factor Inhibitor Drug Manufacturers, Product Type & Application Table 13. Global Tumor Necrosis Factor Inhibitor Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tumor Necrosis Factor Inhibitor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Humira Table 17. Major Manufacturers of Enbrel Table 18. Major Manufacturers of Biosimilars Table 19. Major Manufacturers of Cimzia Table 20. Major Manufacturers of Simponi Table 21. Major Manufacturers of Remicade Table 22. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2026) Table 26. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2027-2032) Table 27. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2026) Table 31. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Juvenile Idiopathic Arthritis Table 33. Major Manufacturers of Psoriatic Arthritis Table 34. Major Manufacturers of Rheumatoid Arthritis Table 35. Major Manufacturers of Ulcerative Colitis Table 36. Major Manufacturers of Crohn’s Disease Table 37. Major Manufacturers of Others Table 38. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2026) & (K Units) Table 40. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2027-2032) & (K Units) Table 41. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2026) Table 42. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2027-2032) Table 43. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 44. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021-2026) & (K Units) Table 45. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2027-2032) & (K Units) Table 46. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2026) Table 47. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2027-2032) Table 48. Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2021-2026) & (K Units) Table 50. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2021-2026) Table 51. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 52. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units) Table 55. North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units) Table 56. Europe Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units) Table 58. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units) Table 59. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units) Table 61. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units) Table 62. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 63. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units) Table 64. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units) Table 65. Global Tumor Necrosis Factor Inhibitor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2021-2026) Table 69. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2027-2032) Table 70. UCB Company Information Table 71. UCB Business Overview Table 72. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 74. UCB Recent Development Table 75. Shanghai Pharmaceuticals Holding Co., Ltd. Company Information Table 76. Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview Table 77. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 79. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Development Table 80. Johnson & Johnson Company Information Table 81. Johnson & Johnson Business Overview Table 82. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 84. Johnson & Johnson Recent Development Table 85. Novartis AG Company Information Table 86. Novartis AG Business Overview Table 87. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 89. Novartis AG Recent Development Table 90. Merck & Co., Inc. Company Information Table 91. Merck & Co., Inc. Business Overview Table 92. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 94. Merck & Co., Inc. Recent Development Table 95. Pfizer, Inc. Company Information Table 96. Pfizer, Inc. Business Overview Table 97. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 99. Pfizer, Inc. Recent Development Table 100. Amgen Inc. Company Information Table 101. Amgen Inc. Business Overview Table 102. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 104. Amgen Inc. Recent Development Table 105. AbbVie Inc. Company Information Table 106. AbbVie Inc. Business Overview Table 107. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 109. AbbVie Inc. Recent Development Table 110. PROBIOMED Company Information Table 111. PROBIOMED Business Overview Table 112. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 114. PROBIOMED Recent Development Table 115. LEO Pharma Company Information Table 116. LEO Pharma Business Overview Table 117. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 119. LEO Pharma Recent Development Table 120. EPIRUS Biopharmaceuticals Company Information Table 121. EPIRUS Biopharmaceuticals Business Overview Table 122. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 124. EPIRUS Biopharmaceuticals Recent Development Table 125. CASI Pharmaceuticals Company Information Table 126. CASI Pharmaceuticals Business Overview Table 127. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio Table 129. CASI Pharmaceuticals Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Tumor Necrosis Factor Inhibitor Drug Distributors List Table 133. Tumor Necrosis Factor Inhibitor Drug Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Inhibitor Drug Product Image Figure 2. Global Tumor Necrosis Factor Inhibitor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Inhibitor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Inhibitor Drug Sales (2021-2032) & (K Units) Figure 5. Global Tumor Necrosis Factor Inhibitor Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tumor Necrosis Factor Inhibitor Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Humira Image Figure 9. Enbrel Image Figure 10. Biosimilars Image Figure 11. Cimzia Image Figure 12. Simponi Image Figure 13. Remicade Image Figure 14. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2032) Figure 17. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2032) Figure 20. Juvenile Idiopathic Arthritis Image Figure 21. Psoriatic Arthritis Image Figure 22. Rheumatoid Arthritis Image Figure 23. Ulcerative Colitis Image Figure 24. Crohn’s Disease Image Figure 25. Others Image Figure 26. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2032) Figure 29. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2032) Figure 32. North America Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. North America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 34. U.S. Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Canada Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Mexico Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 39. Germany Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. France Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. U.K. Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Italy Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Netherlands Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 46. China Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Japan Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Korea Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. India Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Australia Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 54. Brazil Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. South Africa Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Saudi Arabia Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Turkey Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Argentina Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. UAE Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Egypt Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Chile Tumor Necrosis Factor Inhibitor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 62. Global Tumor Necrosis Factor Inhibitor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 65. North America Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 67. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Tumor Necrosis Factor Inhibitor Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Tumor Necrosis Factor Inhibitor Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Humira
  • Enbrel
  • Biosimilars
  • Cimzia
  • Simponi
  • Remicade
Applications
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Crohn’s Disease
  • Others
Companies covered
  • UCB
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • PROBIOMED
  • LEO Pharma
  • EPIRUS Biopharmaceuticals
  • CASI Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Inhibitor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Inhibitor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tumor Necrosis Factor Inhibitor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tumor Necrosis Factor Inhibitor Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tumor Necrosis Factor Inhibitor Drug Market Dynamics
  1. 2.1 Tumor Necrosis Factor Inhibitor Drug Industry Trends
  2. 2.2 Tumor Necrosis Factor Inhibitor Drug Industry Drivers
  3. 2.3 Tumor Necrosis Factor Inhibitor Drug Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Inhibitor Drug Industry Restraints
3 Tumor Necrosis Factor Inhibitor Drug Market by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Inhibitor Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Inhibitor Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Inhibitor Drug Manufacturers, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Inhibitor Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Inhibitor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Inhibitor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Inhibitor Drug Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Inhibitor Drug Market by Type
  1. 4.1 Tumor Necrosis Factor Inhibitor Drug Type Introduction
  2. 4.1.1 Humira
  3. 4.1.2 Enbrel
  4. 4.1.3 Biosimilars
  5. 4.1.4 Cimzia
  6. 4.1.5 Simponi
  7. 4.1.6 Remicade
  8. 4.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type
  9. 4.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type
  13. 4.3.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2032)
5 Tumor Necrosis Factor Inhibitor Drug Market by Application
  1. 5.1 Tumor Necrosis Factor Inhibitor Drug Application Introduction
  2. 5.1.1 Juvenile Idiopathic Arthritis
  3. 5.1.2 Psoriatic Arthritis
  4. 5.1.3 Rheumatoid Arthritis
  5. 5.1.4 Ulcerative Colitis
  6. 5.1.5 Crohn’s Disease
  7. 5.1.6 Others
  8. 5.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application
  9. 5.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2032)
  11. 5.2.3 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2032)
  12. 5.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application
  13. 5.3.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021-2032)
  15. 5.3.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2032)
6 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region
  1. 6.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region
  1. 7.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region
  2. 7.1.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032)
  8. 7.2.2 North America Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032)
  11. 7.3.2 Europe Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Shanghai Pharmaceuticals Holding Co., Ltd.
  8. 8.2.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
  9. 8.2.2 Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview
  10. 8.2.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  12. 8.2.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Merck & Co., Inc.
  26. 8.5.1 Merck & Co., Inc. Company Information
  27. 8.5.2 Merck & Co., Inc. Business Overview
  28. 8.5.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  30. 8.5.5 Merck & Co., Inc. Recent Developments
  31. 8.6 Pfizer, Inc.
  32. 8.6.1 Pfizer, Inc. Company Information
  33. 8.6.2 Pfizer, Inc. Business Overview
  34. 8.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  36. 8.6.5 Pfizer, Inc. Recent Developments
  37. 8.7 Amgen Inc.
  38. 8.7.1 Amgen Inc. Company Information
  39. 8.7.2 Amgen Inc. Business Overview
  40. 8.7.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  42. 8.7.5 Amgen Inc. Recent Developments
  43. 8.8 AbbVie Inc.
  44. 8.8.1 AbbVie Inc. Company Information
  45. 8.8.2 AbbVie Inc. Business Overview
  46. 8.8.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  48. 8.8.5 AbbVie Inc. Recent Developments
  49. 8.9 PROBIOMED
  50. 8.9.1 PROBIOMED Company Information
  51. 8.9.2 PROBIOMED Business Overview
  52. 8.9.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  54. 8.9.5 PROBIOMED Recent Developments
  55. 8.10 LEO Pharma
  56. 8.10.1 LEO Pharma Company Information
  57. 8.10.2 LEO Pharma Business Overview
  58. 8.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  60. 8.10.5 LEO Pharma Recent Developments
  61. 8.11 EPIRUS Biopharmaceuticals
  62. 8.11.1 EPIRUS Biopharmaceuticals Company Information
  63. 8.11.2 EPIRUS Biopharmaceuticals Business Overview
  64. 8.11.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  66. 8.11.5 EPIRUS Biopharmaceuticals Recent Developments
  67. 8.12 CASI Pharmaceuticals
  68. 8.12.1 CASI Pharmaceuticals Company Information
  69. 8.12.2 CASI Pharmaceuticals Business Overview
  70. 8.12.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
  72. 8.12.5 CASI Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tumor Necrosis Factor Inhibitor Drug Value Chain Analysis
  2. 9.1.1 Tumor Necrosis Factor Inhibitor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tumor Necrosis Factor Inhibitor Drug Production Mode & Process
  6. 9.2 Tumor Necrosis Factor Inhibitor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tumor Necrosis Factor Inhibitor Drug Distributors
  9. 9.2.3 Tumor Necrosis Factor Inhibitor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst